Will dabrafenib targeted drug be reimbursed in 2024?

Dabrafenib (Dabrafenib) belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps stop the spread of cancer cells.

Dabrafenib is used alone or in combination with trametinib to treat melanoma that has spread or cannot be removed with surgery. It is also used with trametinib to help prevent recurrence of melanoma after surgery. It is used only if the melanoma cells have the BRAF V600E or V600K mutation.

Dabrafenib is also used with trametinib to treat non-small cell lung cancer (NSCLC) that has spread and unchanged thyroid cancer (ATC) that has spread and has no satisfactory treatment options. Use only if NSCLC cells and ATC cells have the BRAF V600E mutation. Dabrafenib is also used in combination with trametinib to treat solid tumors that have spread, cannot be removed by surgery, or have worsened (progressed) and for which there are no satisfactory treatment options. It is used only if the solid tumor has the BRAF V600E mutation. Dabrafenib is also used in combination with trametinib to treat low-grade glioma (LGG) in patients who require other treatments. Used only if the brain tumor has the BRAF V600E mutation. Your doctor will use special tests to look for these mutations. Dabrafenib is an anti-tumor drug.

In summary, dabrafenib, as a targeted therapy, has shown good efficacy in the treatment of specific types of tumors, but patients still need to pay attention to its potential side effects and indication limitations when using it.

In short, patients should consult a professional doctor before using any medicine, and the doctor will judge and provide medication guidance.

Dabrafenib has now been successfully launched in my country and has been included in the reimbursement list of medical insurance, providing patients with more benefits. The original dabrafenib drug available in the domestic market is available in two specifications: 75 mg 120 tablets and 50 mg 120 tablets. With the help of medical insurance policies, the price of 75 mg medicine has been adjusted to about 12,000 yuan. In addition, dabrafenib has also received great attention overseas, and its products include original drugs and generic drugs. In particular, the 75mg 120-capsule original version of dabrafenib produced by Novartis is priced at 11,000 yuan per box in Turkey. At the same time, there are many generic versions of dabrafenib on the market to choose from. These generic drugs all use a unified specification of 75 mg and 120 pills, and the price is generally stable at around 2,700 yuan.